 Applied Therapeutics NASDAQ: APLT is trading significantly lower Monday after the company said it would not immediately submit a new drug application for its AT-007 for treatment of galactosemia. The Galactosemia program had previously been discussed in the context of an NDA for accelerated approval based on reduction in galactitol, but the FDA has now indicated that clinical outcomes data will likely be required for approval. 